ESMO News

FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer

noreply@esmo.org — Fri, 19 Sep 2025 07:09:00 +00:00

Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study

ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use

noreply@esmo.org — Thu, 18 Sep 2025 12:09:00 +00:00

With tobacco continuing to be one of the main contributors to preventable cancers globally, it is important that robust policy measures are taken to promote tobacco cessation and reduce premature deaths linked to smoking

EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim

noreply@esmo.org — Thu, 18 Sep 2025 07:09:00 +00:00

Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002

Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package

noreply@esmo.org — Wed, 17 Sep 2025 08:09:00 +00:00

With an estimated 40% of all cancers being preventable, ESMO considers it crucial that consumers receive the right information about the cancer-risks linked to alcohol and that public health prevails over commercial interests

ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular Health Plan

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

The European Society for Medical Oncology (ESMO) has submitted its response to the European Commission’s consultation on the proposed EU Cardiovascular Health Plan

Amivantamab-Lazertinib Prolongs OS Over Osimertinib Therapy Among Patients with Previously Untreated EGFR-mutated Advanced NSCLC

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

Findings from the final analysis of the MARIPOSA study

Immune interception represents an exciting opportunity to stop cancer in its tracks

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions

Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Diverse approaches are investigated in oncology that also include the use of artificial intelligence

Chemoradiotherapy Enables R0 Resection in Patients with Locally Unresectable Pancreatic Cancer More Often Than Chemotherapy Alone

noreply@esmo.org — Tue, 16 Sep 2025 07:09:00 +00:00

Findings from the CONKO-007 study

Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis

noreply@esmo.org — Mon, 15 Sep 2025 14:09:00 +00:00

Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment

A Novel Assay Identifies a Subpopulation of High-Risk Patients with Good Prognosis After Standard Adjuvant Therapies for EBC

noreply@esmo.org — Mon, 15 Sep 2025 07:09:00 +00:00

It integrates clinicopathologic variables and slide-derived features capturing tumour architecture, microenvironment, and proliferation

EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab

noreply@esmo.org — Fri, 12 Sep 2025 08:09:00 +00:00

Bilprevda is highly similar to the reference product Xgeva, which was authorised in the EU in 2011

EMA Recommends Extension of Indications for Ibrutinib

noreply@esmo.org — Thu, 11 Sep 2025 07:09:00 +00:00

New indication concerns the first-line treatment of adult patients with mantle cell lymphoma who are eligible for autologous stem cell transplantation

ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme

noreply@esmo.org — Wed, 10 Sep 2025 09:09:00 +00:00

The health programmes of the European Union (EU) are important policy instruments for improving Europe’s healthcare systems, enhancing the quality of cancer care, and delivering tangible solutions that benefit patients with cancer

ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce

noreply@esmo.org — Wed, 10 Sep 2025 08:09:00 +00:00

ESMO is calling on EU policymakers to prioritise the wellbeing of the oncology workforce by adopting legislative and policy measures to prevent burnout.

ESMO awards its first fellowship to support digital and computational pathology

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

Findings from the LEAP-003 study

Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC

noreply@esmo.org — Tue, 09 Sep 2025 07:09:00 +00:00

Findings from the A-BRAVE study

Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of Disease, but Compared to Older Have Similar Crude and Better Stage-Adjusted Survival

noreply@esmo.org — Mon, 08 Sep 2025 07:09:00 +00:00

Findings from a Swedish cohort study

A toolkit to address disparities in digitally enabled oncology trials

noreply@esmo.org — Fri, 05 Sep 2025 13:09:00 +00:00

An initiative fosters inclusive research by improving patient access and participation in cancer research

FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer

noreply@esmo.org — Fri, 19 Sep 2025 07:09:00 +00:00

Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study

ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use

noreply@esmo.org — Thu, 18 Sep 2025 12:09:00 +00:00

EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim

noreply@esmo.org — Thu, 18 Sep 2025 07:09:00 +00:00

Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002

Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package

noreply@esmo.org — Wed, 17 Sep 2025 08:09:00 +00:00

ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular Health Plan

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

The European Society for Medical Oncology (ESMO) has submitted its response to the European Commission’s consultation on the proposed EU Cardiovascular Health Plan

Amivantamab-Lazertinib Prolongs OS Over Osimertinib Therapy Among Patients with Previously Untreated EGFR-mutated Advanced NSCLC

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

Findings from the final analysis of the MARIPOSA study

Immune interception represents an exciting opportunity to stop cancer in its tracks

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions

Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Diverse approaches are investigated in oncology that also include the use of artificial intelligence

Chemoradiotherapy Enables R0 Resection in Patients with Locally Unresectable Pancreatic Cancer More Often Than Chemotherapy Alone

noreply@esmo.org — Tue, 16 Sep 2025 07:09:00 +00:00

Findings from the CONKO-007 study

Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis

noreply@esmo.org — Mon, 15 Sep 2025 14:09:00 +00:00

Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment

A Novel Assay Identifies a Subpopulation of High-Risk Patients with Good Prognosis After Standard Adjuvant Therapies for EBC

noreply@esmo.org — Mon, 15 Sep 2025 07:09:00 +00:00

It integrates clinicopathologic variables and slide-derived features capturing tumour architecture, microenvironment, and proliferation

EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab

noreply@esmo.org — Fri, 12 Sep 2025 08:09:00 +00:00

Bilprevda is highly similar to the reference product Xgeva, which was authorised in the EU in 2011

EMA Recommends Extension of Indications for Ibrutinib

noreply@esmo.org — Thu, 11 Sep 2025 07:09:00 +00:00

New indication concerns the first-line treatment of adult patients with mantle cell lymphoma who are eligible for autologous stem cell transplantation

ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme

noreply@esmo.org — Wed, 10 Sep 2025 09:09:00 +00:00

ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce

noreply@esmo.org — Wed, 10 Sep 2025 08:09:00 +00:00

ESMO is calling on EU policymakers to prioritise the wellbeing of the oncology workforce by adopting legislative and policy measures to prevent burnout.

ESMO awards its first fellowship to support digital and computational pathology

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

Findings from the LEAP-003 study

Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC

noreply@esmo.org — Tue, 09 Sep 2025 07:09:00 +00:00

Findings from the A-BRAVE study

Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of Disease, but Compared to Older Have Similar Crude and Better Stage-Adjusted Survival

noreply@esmo.org — Mon, 08 Sep 2025 07:09:00 +00:00

Findings from a Swedish cohort study

A toolkit to address disparities in digitally enabled oncology trials

noreply@esmo.org — Fri, 05 Sep 2025 13:09:00 +00:00

An initiative fosters inclusive research by improving patient access and participation in cancer research

FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer

noreply@esmo.org — Fri, 19 Sep 2025 07:09:00 +00:00

Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study

ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use

noreply@esmo.org — Thu, 18 Sep 2025 12:09:00 +00:00

EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim

noreply@esmo.org — Thu, 18 Sep 2025 07:09:00 +00:00

Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002

Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package

noreply@esmo.org — Wed, 17 Sep 2025 08:09:00 +00:00

ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular Health Plan

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

The European Society for Medical Oncology (ESMO) has submitted its response to the European Commission’s consultation on the proposed EU Cardiovascular Health Plan

Amivantamab-Lazertinib Prolongs OS Over Osimertinib Therapy Among Patients with Previously Untreated EGFR-mutated Advanced NSCLC

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

Findings from the final analysis of the MARIPOSA study

Immune interception represents an exciting opportunity to stop cancer in its tracks

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions

Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Diverse approaches are investigated in oncology that also include the use of artificial intelligence

Chemoradiotherapy Enables R0 Resection in Patients with Locally Unresectable Pancreatic Cancer More Often Than Chemotherapy Alone

noreply@esmo.org — Tue, 16 Sep 2025 07:09:00 +00:00

Findings from the CONKO-007 study

Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis

noreply@esmo.org — Mon, 15 Sep 2025 14:09:00 +00:00

Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment

A Novel Assay Identifies a Subpopulation of High-Risk Patients with Good Prognosis After Standard Adjuvant Therapies for EBC

noreply@esmo.org — Mon, 15 Sep 2025 07:09:00 +00:00

It integrates clinicopathologic variables and slide-derived features capturing tumour architecture, microenvironment, and proliferation

EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab

noreply@esmo.org — Fri, 12 Sep 2025 08:09:00 +00:00

Bilprevda is highly similar to the reference product Xgeva, which was authorised in the EU in 2011

EMA Recommends Extension of Indications for Ibrutinib

noreply@esmo.org — Thu, 11 Sep 2025 07:09:00 +00:00

New indication concerns the first-line treatment of adult patients with mantle cell lymphoma who are eligible for autologous stem cell transplantation

ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme

noreply@esmo.org — Wed, 10 Sep 2025 09:09:00 +00:00

ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce

noreply@esmo.org — Wed, 10 Sep 2025 08:09:00 +00:00

ESMO is calling on EU policymakers to prioritise the wellbeing of the oncology workforce by adopting legislative and policy measures to prevent burnout.

ESMO awards its first fellowship to support digital and computational pathology

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

Findings from the LEAP-003 study

Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC

noreply@esmo.org — Tue, 09 Sep 2025 07:09:00 +00:00

Findings from the A-BRAVE study

Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of Disease, but Compared to Older Have Similar Crude and Better Stage-Adjusted Survival

noreply@esmo.org — Mon, 08 Sep 2025 07:09:00 +00:00

Findings from a Swedish cohort study

A toolkit to address disparities in digitally enabled oncology trials

noreply@esmo.org — Fri, 05 Sep 2025 13:09:00 +00:00

An initiative fosters inclusive research by improving patient access and participation in cancer research

FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer

noreply@esmo.org — Fri, 19 Sep 2025 07:09:00 +00:00

Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study

ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use

noreply@esmo.org — Thu, 18 Sep 2025 12:09:00 +00:00

EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim

noreply@esmo.org — Thu, 18 Sep 2025 07:09:00 +00:00

Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002

Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package

noreply@esmo.org — Wed, 17 Sep 2025 08:09:00 +00:00

ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular Health Plan

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

The European Society for Medical Oncology (ESMO) has submitted its response to the European Commission’s consultation on the proposed EU Cardiovascular Health Plan

Amivantamab-Lazertinib Prolongs OS Over Osimertinib Therapy Among Patients with Previously Untreated EGFR-mutated Advanced NSCLC

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

Findings from the final analysis of the MARIPOSA study

Immune interception represents an exciting opportunity to stop cancer in its tracks

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions

Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Diverse approaches are investigated in oncology that also include the use of artificial intelligence

Chemoradiotherapy Enables R0 Resection in Patients with Locally Unresectable Pancreatic Cancer More Often Than Chemotherapy Alone

noreply@esmo.org — Tue, 16 Sep 2025 07:09:00 +00:00

Findings from the CONKO-007 study

Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis

noreply@esmo.org — Mon, 15 Sep 2025 14:09:00 +00:00

Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment

A Novel Assay Identifies a Subpopulation of High-Risk Patients with Good Prognosis After Standard Adjuvant Therapies for EBC

noreply@esmo.org — Mon, 15 Sep 2025 07:09:00 +00:00

It integrates clinicopathologic variables and slide-derived features capturing tumour architecture, microenvironment, and proliferation

EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab

noreply@esmo.org — Fri, 12 Sep 2025 08:09:00 +00:00

Bilprevda is highly similar to the reference product Xgeva, which was authorised in the EU in 2011

EMA Recommends Extension of Indications for Ibrutinib

noreply@esmo.org — Thu, 11 Sep 2025 07:09:00 +00:00

New indication concerns the first-line treatment of adult patients with mantle cell lymphoma who are eligible for autologous stem cell transplantation

ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme

noreply@esmo.org — Wed, 10 Sep 2025 09:09:00 +00:00

ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce

noreply@esmo.org — Wed, 10 Sep 2025 08:09:00 +00:00

ESMO is calling on EU policymakers to prioritise the wellbeing of the oncology workforce by adopting legislative and policy measures to prevent burnout.

ESMO awards its first fellowship to support digital and computational pathology

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

Findings from the LEAP-003 study

Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC

noreply@esmo.org — Tue, 09 Sep 2025 07:09:00 +00:00

Findings from the A-BRAVE study

Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of Disease, but Compared to Older Have Similar Crude and Better Stage-Adjusted Survival

noreply@esmo.org — Mon, 08 Sep 2025 07:09:00 +00:00

Findings from a Swedish cohort study

A toolkit to address disparities in digitally enabled oncology trials

noreply@esmo.org — Fri, 05 Sep 2025 13:09:00 +00:00

An initiative fosters inclusive research by improving patient access and participation in cancer research

FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer

noreply@esmo.org — Fri, 19 Sep 2025 07:09:00 +00:00

Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study

ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use

noreply@esmo.org — Thu, 18 Sep 2025 12:09:00 +00:00

EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim

noreply@esmo.org — Thu, 18 Sep 2025 07:09:00 +00:00

Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002

Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package

noreply@esmo.org — Wed, 17 Sep 2025 08:09:00 +00:00

ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular Health Plan

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

The European Society for Medical Oncology (ESMO) has submitted its response to the European Commission’s consultation on the proposed EU Cardiovascular Health Plan

Amivantamab-Lazertinib Prolongs OS Over Osimertinib Therapy Among Patients with Previously Untreated EGFR-mutated Advanced NSCLC

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

Findings from the final analysis of the MARIPOSA study

Immune interception represents an exciting opportunity to stop cancer in its tracks

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions

Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Diverse approaches are investigated in oncology that also include the use of artificial intelligence

Chemoradiotherapy Enables R0 Resection in Patients with Locally Unresectable Pancreatic Cancer More Often Than Chemotherapy Alone

noreply@esmo.org — Tue, 16 Sep 2025 07:09:00 +00:00

Findings from the CONKO-007 study

Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis

noreply@esmo.org — Mon, 15 Sep 2025 14:09:00 +00:00

Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment

A Novel Assay Identifies a Subpopulation of High-Risk Patients with Good Prognosis After Standard Adjuvant Therapies for EBC

noreply@esmo.org — Mon, 15 Sep 2025 07:09:00 +00:00

It integrates clinicopathologic variables and slide-derived features capturing tumour architecture, microenvironment, and proliferation

EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab

noreply@esmo.org — Fri, 12 Sep 2025 08:09:00 +00:00

Bilprevda is highly similar to the reference product Xgeva, which was authorised in the EU in 2011

EMA Recommends Extension of Indications for Ibrutinib

noreply@esmo.org — Thu, 11 Sep 2025 07:09:00 +00:00

New indication concerns the first-line treatment of adult patients with mantle cell lymphoma who are eligible for autologous stem cell transplantation

ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme

noreply@esmo.org — Wed, 10 Sep 2025 09:09:00 +00:00

ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce

noreply@esmo.org — Wed, 10 Sep 2025 08:09:00 +00:00

ESMO is calling on EU policymakers to prioritise the wellbeing of the oncology workforce by adopting legislative and policy measures to prevent burnout.

ESMO awards its first fellowship to support digital and computational pathology

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

Findings from the LEAP-003 study

Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC

noreply@esmo.org — Tue, 09 Sep 2025 07:09:00 +00:00

Findings from the A-BRAVE study

Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of Disease, but Compared to Older Have Similar Crude and Better Stage-Adjusted Survival

noreply@esmo.org — Mon, 08 Sep 2025 07:09:00 +00:00

Findings from a Swedish cohort study

A toolkit to address disparities in digitally enabled oncology trials

noreply@esmo.org — Fri, 05 Sep 2025 13:09:00 +00:00

An initiative fosters inclusive research by improving patient access and participation in cancer research

FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer

noreply@esmo.org — Fri, 19 Sep 2025 07:09:00 +00:00

Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study

ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use

noreply@esmo.org — Thu, 18 Sep 2025 12:09:00 +00:00

EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim

noreply@esmo.org — Thu, 18 Sep 2025 07:09:00 +00:00

Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002

Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package

noreply@esmo.org — Wed, 17 Sep 2025 08:09:00 +00:00

ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular Health Plan

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

The European Society for Medical Oncology (ESMO) has submitted its response to the European Commission’s consultation on the proposed EU Cardiovascular Health Plan

Amivantamab-Lazertinib Prolongs OS Over Osimertinib Therapy Among Patients with Previously Untreated EGFR-mutated Advanced NSCLC

noreply@esmo.org — Wed, 17 Sep 2025 07:09:00 +00:00

Findings from the final analysis of the MARIPOSA study

Immune interception represents an exciting opportunity to stop cancer in its tracks

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions

Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity

noreply@esmo.org — Tue, 16 Sep 2025 12:09:00 +00:00

Diverse approaches are investigated in oncology that also include the use of artificial intelligence

Chemoradiotherapy Enables R0 Resection in Patients with Locally Unresectable Pancreatic Cancer More Often Than Chemotherapy Alone

noreply@esmo.org — Tue, 16 Sep 2025 07:09:00 +00:00

Findings from the CONKO-007 study

Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis

noreply@esmo.org — Mon, 15 Sep 2025 14:09:00 +00:00

Presented studies explore different approaches to predict cancer cachexia and inform on the intra-tumour heterogeneity to personalise treatment

A Novel Assay Identifies a Subpopulation of High-Risk Patients with Good Prognosis After Standard Adjuvant Therapies for EBC

noreply@esmo.org — Mon, 15 Sep 2025 07:09:00 +00:00

It integrates clinicopathologic variables and slide-derived features capturing tumour architecture, microenvironment, and proliferation

EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab

noreply@esmo.org — Fri, 12 Sep 2025 08:09:00 +00:00

Bilprevda is highly similar to the reference product Xgeva, which was authorised in the EU in 2011

EMA Recommends Extension of Indications for Ibrutinib

noreply@esmo.org — Thu, 11 Sep 2025 07:09:00 +00:00

New indication concerns the first-line treatment of adult patients with mantle cell lymphoma who are eligible for autologous stem cell transplantation

ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme

noreply@esmo.org — Wed, 10 Sep 2025 09:09:00 +00:00

ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce

noreply@esmo.org — Wed, 10 Sep 2025 08:09:00 +00:00

ESMO is calling on EU policymakers to prioritise the wellbeing of the oncology workforce by adopting legislative and policy measures to prevent burnout.

ESMO awards its first fellowship to support digital and computational pathology

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma

noreply@esmo.org — Wed, 10 Sep 2025 07:09:00 +00:00

Findings from the LEAP-003 study

Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC

noreply@esmo.org — Tue, 09 Sep 2025 07:09:00 +00:00

Findings from the A-BRAVE study

Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of Disease, but Compared to Older Have Similar Crude and Better Stage-Adjusted Survival

noreply@esmo.org — Mon, 08 Sep 2025 07:09:00 +00:00

Findings from a Swedish cohort study

A toolkit to address disparities in digitally enabled oncology trials

noreply@esmo.org — Fri, 05 Sep 2025 13:09:00 +00:00

An initiative fosters inclusive research by improving patient access and participation in cancer research